BRIEF-Sab Bio Announces Positive Confirmatory Clinical Results

Reuters12-17

Dec 17 (Reuters) - SAB Biotherapeutics Inc SABS.O:

SAB BIO ANNOUNCES POSITIVE CONFIRMATORY CLINICAL RESULTS FROM THE PHASE 1 STUDY OF SAB-142 IN DEVELOPMENT FOR THE TREATMENT OF STAGE 3 T1D
SAB BIOTHERAPEUTICS INC - SAB-142 WELL-TOLERATED, SUPERIOR SAFETY PROFILE TO RATG
SAB BIOTHERAPEUTICS INC - PHASE 1 DATA CONFIRMS SAB-142 DOES NOT CAUSE SERUM SICKNESS

Source text: ID:nGNX8c9hj0

Further company coverage: SABS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592990462?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592990462","market":"us","top_or_hot":-1,"title":"BRIEF-Sab Bio Announces Positive Confirmatory Clinical Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sab Bio Announces Positive Confirmatory Clinical Results </title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SABS\">SAB Biotherapeutics</a> Inc <span>SABS.O</span>:</p><ul><li><p>SAB BIO ANNOUNCES POSITIVE CONFIRMATORY CLINICAL RESULTS FROM THE PHASE 1 STUDY OF SAB-142 IN DEVELOPMENT FOR THE TREATMENT OF STAGE 3 T1D</p></li><li><p>SAB BIOTHERAPEUTICS INC - SAB-142 WELL-TOLERATED, SUPERIOR SAFETY PROFILE TO RATG</p></li><li><p>SAB BIOTHERAPEUTICS INC - PHASE 1 DATA CONFIRMS SAB-142 DOES NOT CAUSE SERUM SICKNESS</p></li></ul><p>Source text: <span>ID:nGNX8c9hj0</span></p><p>Further company coverage: <span>SABS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sab Bio Announces Positive Confirmatory Clinical Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sab Bio Announces Positive Confirmatory Clinical Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sab Bio Announces Positive Confirmatory Clinical Results </title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SABS\">SAB Biotherapeutics</a> Inc <span>SABS.O</span>:</p><ul><li><p>SAB BIO ANNOUNCES POSITIVE CONFIRMATORY CLINICAL RESULTS FROM THE PHASE 1 STUDY OF SAB-142 IN DEVELOPMENT FOR THE TREATMENT OF STAGE 3 T1D</p></li><li><p>SAB BIOTHERAPEUTICS INC - SAB-142 WELL-TOLERATED, SUPERIOR SAFETY PROFILE TO RATG</p></li><li><p>SAB BIOTHERAPEUTICS INC - PHASE 1 DATA CONFIRMS SAB-142 DOES NOT CAUSE SERUM SICKNESS</p></li></ul><p>Source text: <span>ID:nGNX8c9hj0</span></p><p>Further company coverage: <span>SABS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUADGGJM:1","article_id":"2592990462","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592990462","pubTimestamp":1765976926,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sab Bio Announces Positive Confirmatory Clinical Results Dec 17 (Reuters) - SAB Biotherapeutics Inc SABS.O:SAB BIO ANNOUNCES POSITIVE CONFIRMATORY CLINICAL RESULTS FROM THE PHASE 1 STUDY OF SAB-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SABS":"SAB Biotherapeutics, Inc.","SABSW":"SAB Biotherapeutics, Inc. Warrant"},"translate_title":"简报-Sab Bio宣布积极的确证性临床结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SABS":0.9,"SABSW":0.9},"content_text":"BRIEF-Sab Bio Announces Positive Confirmatory Clinical Results Dec 17 (Reuters) - SAB Biotherapeutics Inc SABS.O:SAB BIO ANNOUNCES POSITIVE CONFIRMATORY CLINICAL RESULTS FROM THE PHASE 1 STUDY OF SAB-142 IN DEVELOPMENT FOR THE TREATMENT OF STAGE 3 T1DSAB BIOTHERAPEUTICS INC - SAB-142 WELL-TOLERATED, SUPERIOR SAFETY PROFILE TO RATGSAB BIOTHERAPEUTICS INC - PHASE 1 DATA CONFIRMS SAB-142 DOES NOT CAUSE SERUM SICKNESSSource text: ID:nGNX8c9hj0Further company coverage: SABS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592990462","isCrawlerRequest":true}